Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06487221 · ClinicalTrials.gov registry record · Phase 2
Avutometinib and Defactinib in Diffuse Gastric Cancer
A Phase 2 study of Gastric Cancer and Stomach Cancer, sponsored by Ryan H. Moy, MD, PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT06487221: Recruiting Phase 2 study of Gastric Cancer and Stomach Cancer, sponsored by Ryan H. Moy, MD, PhD.
NCT06487221 is a Phase 2 study of Gastric Cancer and Stomach Cancer that is actively recruiting participants, run by Ryan H. Moy, MD, PhD. The registered enrollment target is 27 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06487221, a Phase 2 study of Gastric Cancer and Stomach Cancer, is actively recruiting participants, sponsored by Ryan H. Moy, MD, PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.
Primary Outcome
To determine the efficacy of combination defactinib and avutometinib in patients with metastatic diffuse gastric cancer (DGC) as measured by 6-month progression-free survival (PFS) rate. PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Conditions Studied
Interventions
- DRUG Avutometinib
- DRUG Defactinib
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2024-10-28 |
| Est. Completion | 2029-05-30 |
| Phase | Phase 2 |
What NCT06487221 shows while recruiting
NCT06487221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Avutometinib is the first listed.
NCT06487221 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06487221 about?
NCT06487221 is a clinical study titled "Avutometinib and Defactinib in Diffuse Gastric Cancer". The purpose of this study is to determine if the combination study treatment with avutometinib and defactinib will prolong life in participants, is effective in decreasing the size of the tumor(s), and if it is safe in subjects with diffuse-type stomach cancer.
What is the current status of trial NCT06487221?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2024-10-28. Estimated completion is 2029-05-30.
What conditions does trial NCT06487221 study?
This clinical trial studies the following conditions: Gastric Cancer, Stomach Cancer.
What interventions are being tested in trial NCT06487221?
The interventions under investigation include: Avutometinib (DRUG), Defactinib (DRUG).
Who is sponsoring clinical trial NCT06487221?
This trial is sponsored by Ryan H. Moy, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06487221 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06487221's enrollment target sits among peer trials
27 141st of 153 higher than 12 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI